Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow KalVista Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for KalVista Pharmaceuticals, Inc.

KALV

KalVista Pharmaceuticals, Inc.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies for rare diseases, primarily hereditary angioedema (HAE). Its flagship product, EKTERLY (sebetralstat), is an oral on-demand treatment for HAE attacks, targeting plasma kallikrein. The company advances its pipeline through research, strategic licensing, and global regulatory efforts, competing with established biotech and pharma firms in the rare disease space. It emphasizes innovation, intellectual property, and global commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from KalVista Pharmaceuticals, Inc.

1
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports $40.9M Revenue in Latest Quarter, Enters Merger Agreement with Chiesi

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports First Product Revenue of $13.7 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports First Product Revenue of $1.4 Million Following EKTERLY Launch

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports FDA Approval of EKTERLY and Financial Developments for Fiscal Year Ending April 30, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports $48.5 Million Net Loss and Strategic Advancements in Product Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports $42.3 Million Net Loss for Q4 2024, Advances Product Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals Reports Net Loss of $40.4 Million in Latest Quarter, Files New Drug Application with FDA

Via official filing (AI summary) | over 1 year ago | 0 comments